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Impaired phagocytosis in chronic renal failure is mediated by
secondary hyperparathyroidism
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Impaired phagocytosis in chronic renal failure is mediated by second-
ary hyperparathyroidism. Patients with chronic renal failure (CRF)
display impaired phagocytosis by the polymorphonuclear leucocytes
(PMNL), and these cells have elevated basal levels of cytosolic calcium
([Ca2]) and reduced ATP content. It has been suggested that these
changes in PMNL metabolism and function are mediated by the state of
secondary hyperparathyroidism of CRF. To examine the role of excess
PTH in these derangements of PMNL, we studied [Ca2]1, ATP and
phagocytic ability of PMNL in five groups of rats including: CRF, CRF
normocalcemic parathyroidectomized (CRF-PTX), CRF and normal
animals treated with verapamil (CRF-V), and normal-V, respectively.
The level of [Ca2I in the PMNL of CRF rats (149 2.7 nM) was
significantly (P < 0.01) higher and the ATP content (4.2 0.17 nmol/5
x 106 PMNL) significantly lower (P < 0.01) than in normal (108 2.4
nM; 9.5 0.15 nmol/5 x 106 PMNL), CRF-PTX (103 2.9 nM; 9.2
0.19 nmol/5 X 10 PMNL), CRF-V (107 2.2 nM; 9.0 0.2 nmol/5 x
106 PMNL) and normal-V (106 1.8 nM; 9.2 0.2 nmol/5 x 106
PMNL), despite sustained elevation in blood PTH in the CRF-V group.
Phagocytosis was significantly (P < 0.01) impaired in CRF animals (5.6
0.25 g oil/l07 PMNL/min) but was normal in CRF-PTX (9.3 0.21
g oilIlO7 PMNL/min) and CRF-V (9.5 0.22 g oilIlO7 PMNL/min)
rats. The values of phagocytosis in normal and normal-V rats were 9.6
44 and 9.6 0.18 g oil/107 PMNL/min, respectively. The data
indicate that excess PTH in CRF is a major factor underlying the
metabolic and functional derangements in PMNL and that these abnor-
malities are prevented by either reducing the blood levels of PTH or by
blocking its action on PMNL by verapamil.
Impaired phagocytosis has been observed in patients with
chronic renal failure (CRF) [1—3]. Data from our laboratory
have demonstrated that polymorphonuclear leucocytes
(PMNL) from dialysis patients displayed a significant elevation
in their resting levels of cytosolic calcium ([Ca2]), a reduction
in their ATP content and reduced phagocytic ability [31.
PMNL is a target cell for parathyroid hormone (PTH) [4, 5]
and CRF is associated with secondary hyperparathyroidism and
elevated blood levels of PTH [6, 7]. Since PTH is known to
augment calcium entry into cells [8—121, it is plausible that the
elevated blood levels of PTH in dialysis patients are responsi-
ble, at least in part, for the elevation in their [Ca2i. Indeed, we
found a direct and significant relationship between the [Ca2]
Received for publication August 2, 1991
and in revised form January 2, 1992
Accepted for publication January 3, 1992
© 1992 by the International Society of Nephrology
of the PMNL of dialysis patients and their blood levels of PTH
[31.
Increased calcium burden of cells is associated with impaired
mitochondrial oxidation and ATP production and hence a fall in
their ATP content [13—15]. It was, therefore, suggested that the
elevation in [Ca2]1 of PMNL in CRF is responsible for the
decrease in their ATP content [3]. Both the sustained elevation
in [Ca2] and the fall in their ATP content could exert delete-
rious effects on their function and hence contribute to the
impaired phagocytosis in CRF. It is implied, therefore, that the
cellular derangements that lead to reduction in the phagocytic
ability of the PMNL in CRF patients is initiated by the chronic
excess of PTH in these patients.
To definitely incriminate PTH in the genesis of the impaired
phagocytosis in CRF, one must document that [Ca2], ATP
content and phagocytic ability of PMNL are normal in the CRF
state without excess PTH. Also, blocking of PTH-induced entry
of calcium into PMNL in CRF by a calcium channel blocker
should normalize the metabolic and functional abnormalities of
the PMNL despite CRF and elevated blood levels of PTH. The
present study was undertaken to examine these questions.
Methods
Two hundred and fifty male Sprague-Dawley rats weighing
300 to 330 g were studied. They were fed rat chow diet (Wayne
Research Animal Diets, Chicago, Illinois, USA) throughout the
study and allowed to drink ad libitum. The diet contained 1.4%
calcium and 0.97% phosphorus. Five groups of animals were
studied including: (a) normal rats; (b) rats with CRF of 42 days
duration; (c) normocalcemic parathyroidectomized (PTX) rats
with CRF of 42 days duration; (d) rats with CRF of 42 days
duration treated daily with verapamil from day one of CRF; and
(e) normal rats treated with verapamil for 42 days.
Parathyroidectomy was done by electrocautery, and the
success of the procedure was ascertained by a decrease in
plasma levels of calcium of at least 2 mgldl. The PTX rats were
allowed to freely drink water containing 50 glliter of calcium
gluconate. This procedure is adequate to normalize plasma
calcium in PTX rats. Animals that did not display a fall in
plasma calcium of 2 mg!dl or more after PTX, and the PTX rats
that did not attain normocalcemia with drinking calcium con-
taining water were discarded and not used in the study. Seven
days after PTX, the animals underwent right partial nephrec-
tomy through a flank incision; a week later, a left nephrectomy
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was performed. This nephrectomy procedure was also per-
formed in rats with intact parathyroid glands. Verapamil (Isop-
tin, Knoll, AG, Ludwigshafen, Germany) was injected subcu-
taneously in a dose of 0.1 p.g/g body weight twice daily. The
normal rats received subcutaneous injections of vehicle only.
Two days before the experiments, the rats were housed in
metabolic cages for the collection of two 24-hours urine output
which were used for the measurements of creatinine clearance.
On the day of the experiment, the rats were put under light
ether anesthesia and blood was drawn directly from the heart
under sterile conditions. The blood was placed into sterile test
tubes containing 100 U of preservative free heparin (Gibco
Laboratories, Grand Island, New York, USA) per 1 ml of
blood. PMNL were isolated from the whole blood according to
the method described by Ferrante and Thong [16] with modifi-
cation. A total of 3.0 ml of fresh heparinized blood was placed
over two layers of Ficoll-hypaque solution in 15 ml conical
polypropylene tubes. The bottom layer was made of 3 ml
Mono-Poly Resolving Medium with density of 1.114 g/ml (Flow
Laboratories, Inc., McLean, Virginia, USA) and a second layer
of 1.0 ml of Isolymph with density of 1.077 g/ml (Gallard-
Schlesinger Industries Inc., Cane Place, New York, USA). The
tubes were centrifuged at 1270 x g for 45 minutes at room
temperature. This procedure resulted in the separation of
mononuclear and polymorphonuclear cells into two distinct
bands with the red blood cell pellet at the bottom of the tube.
The PMNL were aspirated with Pasteur pipette and washed
twice in Hank's balanced salt solution (HBSS). Cells from two
to three animals were pooled for each study. Cell purity,
determined by Wright's staining, was greater than 97% and cell
viability assayed by the Trypan blue exclusion method ex-
ceeded 98%. Difficulty in the separation of PMNL was encoun-
tered in few blood specimens and this was overcome by
extending the time of centrifugation.
The rate of ingestion by PMNL was estimated spectrophoto-
metrically according to the bioassay described by Southwick
and Stossel [171. Briefly, PMNL were fed oil droplets contain-
ing oil red 0 and coated with Escherichia co!i lipopolysaccha-
ride. These particles were previously opsonized in fresh autol-
ogous serum. After the PMNL and the particles were incubated
for five minutes at 37°C, the reaction was rapidly stopped by
adding ice-cold isotonic saline containing 1 mrvx N-ethylmaleim-
ide which poisons the cells and stops ingestion. Uningested
particles were separated from cells containing ingested particles
by centrifugation at 250 x g for 15 minutes. Oil red 0 was
extracted from the cell pellet with dioxane and the optical
density of the extract was measured in Perkin Elmer Lambda 2
UV/VIS spectrophotometer (Perkin Elmer Corporation, Nor-
walk, Connecticut, USA) at a wavelength of 525 nm. The
ingestion rate was expressed in jig of oil engulfed per l0
PMNL per minute. All reagents were purchased from Aldrich
Chemical Company, Inc. Milwaukee, Wisconsin, USA. Lipo-
polysaccharide Escherichia coli 026:B6 was obtained from
Biovin Preparation, Difco Laboratories (Detroit, Michigan,
USA).
The ATP content of PMNL was measured according to the
method reported by Lundin et al [18]. An aliquot of 0.5 ml of 0.6
M ice-cold perchloric acid (PCA) was added to 5 x 106 PMNL
in 0.5 ml of RPMI (Gibco). After 10 minutes of extraction on
ice, 62.5 pI of 2 M K2C03 was added and the mixture was
centrifuged at 10500 x g for 10 minutes. The supernatant was
removed and immediately frozen with liquid nitrogen and
stored at —70°C. On the day of the assay 50 p1 of the
supernataat was added to 950 p.1 of 40 mM Tris buffer (pH 7.4)
and this mixture was diluted 20 times with distilled water.
Samples of 50 p.1 were assayed for ATP by the firefly lumines-
cence assay with LAD 535 luminometer (Turner Design,
Sunnyvale, California, USA). ATP standards were prepared
with 40 ifiM Tris buffer, distilled water and similar amounts of
RPMI, PCA, K2C03 as in the PMNL preparation.
Resting levels of [Ca2 fj of the PMNL were estimated with
Fura2-AM (Sigma Chemical Co., St. Louis, Missouri, USA). A
sample of S x 106 PMNL was washed with solution I containing
in mM: NaC1, 132; KC1, 3; MgSO4, 1; NaH2PO4, 1.2; D-glucose,
10; HEPES, 10; CaCl2 0.02 (pH was adjusted to 7.4 with Tris
buffer) and spun at 300 x g for 15 minutes. The pellet was
resuspended in 490 p.1 of the above solution and 10 p.1 of
Fura2-AM dissolved in DMSO giving a final concentration of 4
p.M of Fura2-AM. The mixture was then incubated in a water
bath at 37°C for 30 minutes. After this incubation, the cells were
washed and resuspended in solution I. Measurements of [Ca2]
were done with Perkins Elmer fluorescence spectrophotometer
model LS SB at excitation wavelength of 340 nm and 380 nm
and emission wavelength of 510 nm with a slit of 10 and 20 mm,
respectively. An aliquot of 100 p.1 of PMNL suspension was
added to a spectrophotometer cuvette containing 1.9 ml of
solution II, which was the same as solution I except for its
CaC12 concentration being 1 mM. Autofluorescence from cells
and/or added reagents was monitored during each experiment
and was not found to be a significant factor. Maximal fluores-
cence (Fmax) and minimal fluorescence (Fmjn) were measured
with 0.05% Triton and 5 m EGTA in Tris base buffer (pH 8.0),
respectively. Calculation of [Ca2]1 was done using the Grynk-
iewicz, Poenie and Tsien equation [19], and the dissociation
constant for Ca2tFura2 was assumed to be 225 ntvi.
The measurement of calcium in plasma was made with Perkin
Elmer atomic absorption spectrophotometer model 503 (Perkin
Elmer Corp.) and those of creatinine and phosphorus by
Technicon autoanalyzer (Technicon Instrument, Inc., Tarry-
town, New York, USA). PTH levels in serum were determined
by INS-PTH immunoassay kit (Nichols Institute Diagnostics,
San Juan Capistrano, California, USA). This assay recognizes
the aminoterminal fragment of PTH. The lowest detectable
level is 3 pg/ml. The interassay variation is 7.3% and the
intraassay variation is 4%. Statistical evaluation was made with
one way analysis of variance and Tukey's HSD (Honest Statis-
tical Difference) for multiple comparison between groups and
unpaired 1-test for comparison of parameters within each group.
Data are expressed as mean sE.
Results
The effects of the various experimental procedures on body
weight, plasma concentrations of creatinine, calcium, and phos-
phorus, the serum concentrations of PTH and creatinine clear-
ance are shown in Table 1. There were no significant differences
in body weight and in plasma concentrations of calcium among
the five groups of animals. The 5/6 nephrectomy produced a
significant (P C 0.01) rise in plasma concentrations of creatinine
and a significant (P < 0.01) reduction in creatinine clearance;
there were no significant differences in these two parameters
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Table 1. Biochemical data in the five groups of animals studied
Body
weight g
Plasma levels mgldl Creatinine
clearance
pJ/min/100 g
Serum
PTH
pg/miCreatinine Calcium Phosphorus
Normal 315 1.5 0.40 0.02 9.5 0.08 8.0 0.05 527 16 22 0.4
(N = 50)
CRF 311 1.0 1.23 O.O4 9.3 0.13 6.2 0,15b 171 7 49 l.oa
(N = 55)
CRF-PTX 314 1.1 1.17 0.03a 9.5 0.08 8.2 0.08 178 4 15 0.4"
(N = 45)
Normal-V 315 0.8 0.40 0.01 9.5 0,07 8.0 0.06 555 10 21 0.3
(N = 50)
CRF-V 313 1.0 1.22 0.03a 9.4 0.10 6.3 0.13" 181 a 51 l.3a(N = 50)
Data are presented as mean I SE.
a P < 0.01 vs. Normal and Normal-Vb P < 0.01 vs. other 3 groups
P < 0.01 vs. all other groups
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Fig. 1. Resting levels of [Ca2j, of PMNL from the five groups of
animals. Each point represents one study of PMNL pooled from 2 to 3
rats. Brackets denote mean I SE.
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Fig. 2. ATP content of PMNL from the five groups of animals. Each
point represents one study of PMNL pooled from 2 to 3 rats. Brackets
denote mean 1 SE.
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between CRF, CRF-PTX and CRF-V animals. The plasma
phosphorus levels were significantly (P <0.01) lower in CRF
and CRF-V than in the other three groups; lower levels of
serum phosphorus in CRF rats have been observed previously
[20, 21], and this is more likely due to the state of secondary
hyperparathyroidism of CRF since CRF-PTX rats did not
display a similar decrease in plasma phosphorus. The serum
concentrations of PTH were significantly (P < 0.01) higher in
CRF and CRF-V rats than in normal, normal-V and CRF-PTX
animals. The levels of PTH in the CRF-PTX rats were lower (P
<0.01) than normal or normal-V animals.
Figure 1 depicts the [Ca2]1 in PMNL from the five groups of
animals. The PMNL [Ca2] in CRF rats (149 2.7 nM) was
significantly (P < 0.01) higher than in normal (108 2.4 nM),
CRF-PTX (103 2.9 nM), CRF-V (107 2.2 nM) and normal-V
(106 1.8 nM) animals. There were no significant differences
between the values of [Ca2] of PMNL from normal, CRF-
PTX, CRF-V and normal-V.
The ATP content of the PMNL from the CRF rats (4.2 0.17
nmolIS x 106 PMNL) was markedly and significantly (P < 0.01)
lower than in normal (9.5 0.15 nmolIS x 106 PMNL),
CRF-PTX (9.2 0.19 nmoIIS x 10 PMNL), CRF-V (9.0 0.20
nmoLfS x 10 PMNL) and normal-V (9.2 0.22 nmol/5 X 10
PMNL; Fig. 2). There were no significant differences among the
values in the latter four groups of animals.
Phagocytosis by PMNL from CRF rats (5.6 0.25 p.g oi11107
PMNL/min) was impaired and the values were markedly and
significantly (P < 0.01) lower than those of PMNL from normal
(9.6 0.44 PB oilIlO7 PMNL/min), CRF-PTX (9.3 0.21 g
oilJlO7 PMNL/min), CRF-V (9.5 0.22 j.g oil/l07 PMNL/min)
and normal-V (9.6 0.18 p.g oiIIlO7 PMNL/min) animals (Fig.
3). The values in the latter four groups were not different.
Discussion
The results of the present study demonstrate that, as in
humans [1—3], rats with CRF display impaired phagocytosis
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Fig. 3. Ingestion of lipopolysaccharide-coated oil droplets by FMNL
from the five groups of animals. Each point represents one study of
PMNL pooled from 2 to 3 rats. Brackets denote mean 1 SE.
indicating that the rat is an appropriate model for the study of
the mechanisms of impaired phagocytic ability of PMNL in
CRF. Our data further show that the impairment in phagocyto-
sis is prevented by prior parathyroidectomy of CRF rats or by
their treatment with the calcium channel blocker; verapamil.
These observations suggest that either the chronic excess of
PTH per se, and/or a consequence of the action of PTH on
PMNL is responsible for the reduction in their phagocytic
ability. Our findings, that treatment of CRF rats with verapamil
prevented the impairment in phagocytosis despite the sustained
elevation in blood levels of PTH, suggest that the abnormality
in phagocytosis is mediated by an action of PTH that is blocked
by verapamil.
It has been shown that PTH enhances entry of calcium into
many cells [8—12] and this action could cause a sustained rise in
their [Ca21. Indeed, states with chronic excess of PTH in the
absence [21, 221 or presence of CRF [3, 21, 23—25] are associ-
ated with elevation of the basal levels of [Ca2]1 in many cells,
and treatment of CRF animals with verapamil prevented this
rise in [Ca2111 [21, 26]. In our study, the PMNL of CRF
displayed a significant rise in their [Ca2]1, and the elevation in
the latter was also prevented by their treatment with verapamil
despite the maintenance of elevated blood levels of PTH. It
appears, therefore, that verapamil blocks the PTH-induced
augmented entry of calcium into the PMNL. Such a proposition
implies that PTH-induced calcium entry into the PMNL may
directly or indirectly be mediated by activation of the calcium
channels that are blocked by verapamil. It should be mentioned
that available data suggest that PMNL may not have typical
L-type calcium channels [271. However, our observation that
verapamil prevented the rise in [Ca2] in PMNL of CRF rats
suggests that either L-type calcium channels do exist in PMNL,
or other types of calcium channels may be present in PMNL
[28] and are affected by verapamil, or the drug may affect
[Ca2] by other mechanisms, the nature of which have not
been elucidated by our studies.
We would like to propose that the PTH-induced elevation in
[Ca2]1 of the PMNL of the CRF rats directly or indirectly
participates in the genesis of the impaired phagocytosis. Obser-
vations made in other cells have also shown that a sustained rise
in [Ca2]1 interferes with their function; such examples are
found in the impaired insulin secretion by pancreatic islets [22,
25] or abnormal norepinephrine metabolism by brain synapto-
somes [15].
The mechanisms through which a sustained rise in [Ca2]
impairs phagocytosis are not fully understood. A rise in [Ca2]
and an increase in cellular calcium burden impairs mitochon-
drial oxidation and ATP production with consequent fall in ATP
content [13—15, 21, 22, 251. Indeed, the results of the present
study, as those in humans [3], demonstrate that the elevation in
[Ca2]1 of the PMNL is associated with a significant fall in their
ATP content. This fall in ATP content could have a direct
deleterious effect on the phagocytic ability of PMNL. Phago-
cytosis is an active process and requires energy in the form of
ATP [28]. Indeed, impaired phagocytosis is observed in other
clinical states that are associated with low ATP content such as
phosphate depletion [29].
It is of interest that the plasma levels of phosphorus in CRF
and CRF-V animals were lower than those in normal, CRF-PTX
and normal-V rats. It is possible that the elevated serum levels
of PTH in CRF and CRF-V rats are responsible for this fall in
plasma phosphorus. Hyperphosphatemia in humans occurs
when renal function falls below 15 to 20% of normal value [30],
while in our CRF and CRF-V animals the creatinine clearance
was 30% of normal. It is possible that hyperphosphatemia
would have developed in our CRF and CRF-V rats if renal
function had been allowed to fall further. The modest hy-
pophosphatemia in the CRF rats could have contributed to the
impaired phagocytosis since the latter is impaired in both
humans [31] and rats [32] with phosphate depletion. However,
in phosphate depletion the hypophosphatemia is more severe
than that observed in our studies. Further, the finding that
phagocytosis was normal in CRF-V rats suggests that the
modest hypophosphatemia in the CRF rats did not play a
significant role in the impaired phagocytosis. In addition, in a
study on the effect of chronic phosphate depletion on phagocy-
tosis in the rat, we found that the PMNL have high [Ca2]1, and
marked impairment of phagocytosis and normalization of the
[Ca2]1 was associated with almost normal values of phagocy-
tosis despite the hypophosphatemia [32].
Taken together, our data are consistent with the notion that
the chronic elevation of blood levels of PTH in CRF animals
augments entry of calcium into PMNL leading to sustained
elevation in their [Ca211. The rise in the latter inhibits mito-
chondrial oxidation and ATP production. The consequent fall in
ATP content of the PMNL is, at least partly, responsible for the
impaired phagocytosis. This formulation implies that the pre-
vention of the rise of [Ca2]1 in PMNL of CRF rats should result
in normalization of their ATP content and their phagocytic
ability. This is indeed the case in CRF-PTX rats and in CRF rats
treated with verapamil.
Certain data indicate that patients with chronic renal failure
and those treated with hemodialysis may have increased sus-
ceptibility to infection [33, 341. The mechanisms underlying this
phenomenon could be multifactorial including impaired immune
system and defective PMNL function. Our observation pro-
vides evidence for impaired phagocytosis in CRF and potential
mechanisms and therapy of such a defect.
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